Vertex Pharma (VRTX) Tops Q3 EPS by 39c; Raises Revenue Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. EXPE
3. ARM
4. BROS
5. FIS
6. QCOM
7. DDOG
8. EW
9. ZG
10. W

Go back to Vertex Pharma (VRTX) Tops Q3 EPS by 39c; Raises Revenue Outlook

Vertex Reports Third Quarter 2022 Financial Results

October 27, 2022 4:01 PM EDT

Product revenue of $2.33 billion, an 18% increase compared to Q3 2021

Company increases full year 2022 product revenue guidance to $8.8 billion to $8.9 billion

Significant progress in mid- and late-stage pipeline, with near-term commercialization opportunities:

Initiating global exa-cel regulatory submissions for Sickle Cell Disease and Beta Thalassemia in 2022

Initiated Phase 3 clinical studies of VX-548, a novel, selective NaV1.8 inhibitor, in acute pain

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the third... More